[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503640":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":34,"responsibleParty":77,"collaborators":79,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":10,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":10,"enrollmentInfo":92,"targetDuration":10,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"First-degree relative of a patient with a plasma cell dyscrasia or another blood cancer.",null,"Individuals will ensure they are eligible by filling out an eligibility questionnaire confirming they meet all eligibility criteria. Individuals will provide informed consent to complete the baseline questionnaire and provide a blood sample that will be used to determine whether they have a monoclonal protein",[13],"Diagnostic Test: blood sampling",{"label":15,"type":10,"description":16,"interventionNames":17},"Control group","The individuals without a relative of a patient with a plasma cell dyscrasia or another blood cancer.\n\nThis group will undergo the same procedures as the first-degree participants and these data will be used for comparison between the populations.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","blood sampling","Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein",[15,9],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Irit Avivi, Prof","CONTACT","-97236973782","iritavi@tlvmc.gov.il",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Ella Krayzler","-97236947231","ellakr@tlvmc.gov.il",[35,53,66],{"facility":36,"status":37,"city":38,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Soroka","RECRUITING","Beersheba","Israel","IL",{"type":42,"coordinates":43},"Point",[44,45],34.7913,31.25181,{"lat":45,"lon":44},[48,51],{"name":49,"role":27,"phone":10,"phoneExt":10,"email":50},"Miri Zektser, Dr","MIRISP2@clalit.org.il",{"name":49,"role":52,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":54,"status":37,"city":55,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Rabin medical center","Petah Tikva",{"type":42,"coordinates":57},[58,59],34.88747,32.08707,{"lat":59,"lon":58},[62,65],{"name":63,"role":27,"phone":10,"phoneExt":10,"email":64},"Juliana Waxman, Dr","juliava1@clalit.org.il",{"name":63,"role":52,"phone":10,"phoneExt":10,"email":10},{"facility":67,"status":37,"city":68,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"TASMC","Tel Aviv",{"type":42,"coordinates":70},[71,72],34.78057,32.08088,{"lat":72,"lon":71},[75],{"name":76,"role":27,"phone":10,"phoneExt":10,"email":10},"Irit Avivi, MD",{"type":78,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[80],{"name":81,"class":82},"Dana-Farber Cancer Institute","OTHER","100503640","predicting-progression-of-developing-myeloma-in-a-high-risk-screened-population-and-general-population-100503640",false,"NCT05837884","Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population","Inclusion Criteria:\n\n* Must meet criteria of the high-risk population as described with one of the below criteria\n\n  * ≥ 30 years AND\n  * first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.\n\nOR\n\n* Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer '\n* Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care\n\nExclusion Criteria:\n\n* • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.\n\n  * Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia\n  * Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.",true,"ALL","30 Years",{"count":93,"type":94},2000,"ESTIMATED","OBSERVATIONAL","We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.\n\nOur overarching hypothesis is that early detection of MGUS\u002FSMM in a high- risk population, along with the comprehensive characterization of genomic\u002Fepigenomic and microenvironmental\u002Fimmune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.",[98],"Healthy","2026-02-01",{"date":101,"type":102},"2026-02-04","ACTUAL",{"date":104,"type":102},"2023-09-05",{"date":106,"type":94},"2028-06",{"name":5,"class":6},3]